Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

REX CAMPBELL GARLAND

Allopathic & Osteopathic Physicians Internal Medicine Hematology & Oncology

NPI
1902241813
CMS profile
673872
Location
TEMPLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2025 · Entire year

$190.17

2 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2025 · entire year · sorted by reported total

Nature of paymentAmountRecords
Education $99.99 1
Food and Beverage $90.18 1

By paying entity

PY2025 · entire year · sorted by reported total

Paying entityAmountRecords
Janssen Biotech, Inc. $99.99 1
RECORDATI_RARE_DISEASES_INC. $90.18 1

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

REX CAMPBELL GARLAND

NPI 1902241813 · CMS profile ID 673872

Allopathic & Osteopathic Physicians / Internal Medicine / Hematology & Oncology

TEMPLE, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1902241813?year=2025&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
REX CAMPBELL GARLAND, NPI 1902241813, CMS profile ID 673872. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1902241813?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
APA 7
IndustryPayments. (2026). REX CAMPBELL GARLAND, NPI 1902241813, CMS profile ID 673872. General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1902241813?year=2025&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e.
Bluebook
REX CAMPBELL GARLAND, NPI 1902241813, CMS profile ID 673872, IndustryPayments, General Payments, PY2025; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–2 of 2 matching records. This page contains 2 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/fb0b1734-1410-429d-92f6-3f4b35218e5e. https://industrypayments.org/provider/npi-1902241813?year=2025&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2025 · Physicians and non-physician practitioners · CMS publication 2026-06-30

2 matching records · $190.17 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 2 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–2 of 2.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
RECORDATI_RARE_DISEASES_INC. $90.1807/17/2025 Food and Beverage No dispute reported Delay: No
Change: NEW
06/30/2026 1181715830 CMS
Janssen Biotech, Inc. $99.9907/02/2025 Education No dispute reported Delay: No
Change: NEW
06/30/2026 1175166168 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $114.32 1
PY2020 $70.31 1
PY2021 $153.45 6
PY2022 $127.77 2
PY2023 $507.82 5
PY2024 $403.03 4
PY2025 $190.17 2

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $965,516.14 86
PY2024 Principal investigator $293,948.30 30
PY2023 Principal investigator $62,636.64 9
PY2022 Principal investigator $43,443.95 10
PY2021 Principal investigator $129,407.72 30
PY2020 Principal investigator $118,313.60 29

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

30 records in PY2021

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 ABBVIE INC. $250.00 12/28/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 792488473
Principal investigator 1 ABBVIE INC. $2,000.00 11/24/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Na?ve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy No dispute reported 06/30/2026 792484131
Principal investigator 1 PFIZER INC. $22,957.50 11/24/2021 Non-covered Recipient Entity
Baylor Health Care System
AN OPENLABEL 3ARM MULTICENTER RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB PF06863135 MONOTHERAPY AND ELRANATAMAB DARATUMUMAB VERSUS DARATUMUMAB POMALIDOMIDE DEXAMETHASONE IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR No dispute reported 06/30/2026 832624871
Principal investigator 1 ABBVIE INC. $1,800.00 10/26/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) No dispute reported 06/30/2026 792480363
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/30/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 809488613
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 09/30/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 809489341
Principal investigator 1 GlaxoSmithKline, LLC. $4,500.00 09/30/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 809497023
Principal investigator 1 GlaxoSmithKline, LLC. $371.00 09/30/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 809497025
Principal investigator 1 GlaxoSmithKline, LLC. $750.00 09/30/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 809524621
Principal investigator 1 PFIZER INC. $900.00 08/30/2021 Covered Recipient Teaching Hospital
Scott And White Memorial Hospital
AN OPENLABEL 3ARM MULTICENTER RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB PF06863135 MONOTHERAPY AND ELRANATAMAB DARATUMUMAB VERSUS DARATUMUMAB POMALIDOMIDE DEXAMETHASONE IN PARTICIPANTS WITH RELAPSEDREFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR No dispute reported 06/30/2026 832507757
Principal investigator 1 ABBVIE INC. $3,800.00 08/19/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 792472491
Principal investigator 1 ABBVIE INC. $452.00 06/11/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Na?ve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy No dispute reported 06/30/2026 792462965
Principal investigator 1 ABBVIE INC. $2,000.00 05/11/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Na?ve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy No dispute reported 06/30/2026 792456451
Principal investigator 1 ABBVIE INC. $233.60 04/01/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 792441421
Principal investigator 2 Celgene Corporation $3,300.00 03/19/2021 Non-covered Recipient Entity
Baylor Research Institute
LONG-TERM FOLLOW-UP PROTOCOL FOR SUBJECTS TREATED No dispute reported 06/30/2026 807113139
Principal investigator 1 TerSera Therapeutics LLC $3,971.00 03/15/2021 Non-covered Recipient Entity
Baylor Scott & White
A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions No dispute reported 06/30/2026 845547585
Principal investigator 1 ABBVIE INC. $496.36 03/11/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) No dispute reported 06/30/2026 792433079
Principal investigator 1 ABBVIE INC. $595.89 03/11/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 792433347
Principal investigator 1 GlaxoSmithKline, LLC. $874.02 02/24/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 809477837
Principal investigator 1 ABBVIE INC. $250.00 02/18/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 792424485
Principal investigator 1 ABBVIE INC. $23,872.50 01/14/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Randomized, Double-Blind, Phase 3 Study Evaluating the Safety and Efficacy of Venetoclax in Combination with Azacitidine in Patients Newly Diagnosed with Higher-Risk Myelodysplastic Syndrome (Higher-Risk MDS) No dispute reported 06/30/2026 792409067
Principal investigator 1 ABBVIE INC. $2,550.00 01/14/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Na?ve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy No dispute reported 06/30/2026 792409079
Principal investigator 1 ABBVIE INC. $377.00 01/14/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Randomized, Double-Blind, Placebo Controlled Phase 3 Study of Venetoclax in Combination with Azacitidine Versus Azacitidine in Treatment Na?ve Subjects with Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy No dispute reported 06/30/2026 792409085
Principal investigator 1 GlaxoSmithKline, LLC. $65.00 01/12/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTE
DREAMM 7: A MULTICENTER, OPEN-LABEL, RANDOMIZED PHASE III STUDY TO EVA No dispute reported 06/30/2026 809480155
Principal investigator 1 TerSera Therapeutics LLC $9,557.94 01/11/2021 Non-covered Recipient Entity
Baylor Scott & White
A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions No dispute reported 06/30/2026 845547577
Principal investigator 1 TerSera Therapeutics LLC $9,876.44 01/11/2021 Non-covered Recipient Entity
Baylor Scott & White
A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions No dispute reported 06/30/2026 845547579
Principal investigator 1 TerSera Therapeutics LLC $5,415.97 01/11/2021 Non-covered Recipient Entity
Baylor Scott & White
A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions No dispute reported 06/30/2026 845547581
Principal investigator 1 TerSera Therapeutics LLC $318.50 01/11/2021 Non-covered Recipient Entity
Baylor Scott & White
A Phase 2 Exploratory Study of Intravenous Quzyttir (Cetirizine HCl Injection) Versus IV Diphenhydramine in the Prevention of Hypersesitivity Infusion Reactions No dispute reported 06/30/2026 845547583
Principal investigator 1 ABBVIE INC. $23,873.00 01/07/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 792408267
Principal investigator 1 ABBVIE INC. $2,000.00 01/07/2021 Non-covered Recipient Entity
BAYLOR RESEARCH INSTITUTUE
A Phase 2, Open-Label, Multi-Center Study of Venetoclax in Combination with Carfilzomib and Dexamethasone in Subjects with Relapsed or Refractory Multiple Myeloma No dispute reported 06/30/2026 792408273